House Oversight chair presses FDA on China amid growing tensions
House Oversight Committee Chair James Comer (R-KY) is pressing the FDA to share more information on its presence in China amid growing concerns on Capitol Hill about Chinese involvement in biotech and other industries.
The FDA’s monitoring activities in China haven’t been compliant since before the Covid-19 pandemic, Comer wrote in a 14-page letter sent to FDA Commissioner Robert Califf. The letter underscores that China is a dominant manufacturer of active pharmaceutical ingredients and that quality control issues at Chinese facilities have led to shortages of drugs and devices.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
